Kiniksa Pharmaceuticals (NASDAQ:KNSA) Posts Earnings Results, Misses Estimates By $0.11 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA) issued its quarterly earnings results on Tuesday. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.11), Briefing.com reports. Kiniksa Pharmaceuticals had a negative return on equity of 6.12% and a net margin of 5.11%. The company had revenue of $79.90 million during the quarter, compared to the consensus estimate of $76.97 million. During the same period in the previous year, the company earned ($0.18) EPS. Kiniksa Pharmaceuticals’s quarterly revenue was up 65.4% on a year-over-year basis.

Kiniksa Pharmaceuticals Price Performance

KNSA traded up $0.64 on Wednesday, reaching $18.32. 34,133 shares of the company’s stock were exchanged, compared to its average volume of 398,011. The stock’s fifty day moving average price is $19.36 and its 200-day moving average price is $18.00. Kiniksa Pharmaceuticals has a twelve month low of $10.65 and a twelve month high of $22.09. The stock has a market cap of $1.29 billion, a PE ratio of 100.84 and a beta of 0.27.

Insider Buying and Selling

In other news, CAO Michael R. Megna sold 9,659 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $21.45, for a total value of $207,185.55. Following the completion of the transaction, the chief accounting officer now owns 17,588 shares in the company, valued at approximately $377,262.60. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, CAO Michael R. Megna sold 5,126 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total transaction of $111,695.54. Following the sale, the chief accounting officer now owns 17,588 shares of the company’s stock, valued at approximately $383,242.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Michael R. Megna sold 9,659 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $21.45, for a total transaction of $207,185.55. Following the completion of the transaction, the chief accounting officer now owns 17,588 shares in the company, valued at approximately $377,262.60. The disclosure for this sale can be found here. Insiders have sold a total of 33,109 shares of company stock valued at $709,929 in the last ninety days. Company insiders own 54.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Wedbush reiterated an “outperform” rating and issued a $30.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Tuesday. TheStreet upgraded shares of Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research report on Thursday, February 29th.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.